APX 001

Drug Profile

APX 001

Alternative Names: APX-001 - Amplyx Pharmaceuticals

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Antifungals; Antineoplastics; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis; Candidiasis; Aspergillosis; Mycoses
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Mycoses
  • Preclinical Candidiasis

Most Recent Events

  • 01 Nov 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy) in Germany (IV) (NCT03333005)
  • 01 Nov 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy) in Germany (PO) (NCT03333005)
  • 09 Oct 2017 Pharmacokinetics and adverse events data from two phase I trials released by Amplyx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top